HGH Fragment 176-191
Also known as Frag 176-191, HGH Frag, AOD-9401
The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Regulatory Pathway
Dosing Protocol
Typical Dose
250-500 mcg daily
Frequency
1-2x daily, fasted
Duration
8-12 weeks
Timing & Administration
Administer via Subcutaneous injection on empty stomach. Frequency: 1-2x daily, fasted.
Popular Uses
Mechanism of Action
Mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. Stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue.
Research Summary
Evidence level: clinical trials. Clinical status: Investigational - Research ongoing.
Side Effects & Safety
Important Warnings
- Does NOT cause typical HGH side effects
- No effect on IGF-1 levels
- GRAS status.
References
No references available.
Related Peptides
Browse all →A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profileA dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.
View profileA modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
View profile